High-resolution XEOS AURA 10 PET-CT imaging of removed tumor tissue to compare with pathology and outcomes
Official title: A Multicentric, Observational, Post-marketing, Registry Study to Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
Run by XEOS Medical · NCT06970275 · Data updated 2026-11-12
This registry will test whether high-resolution PET-CT scans of removed tumor tissue using the XEOS AURA 10 match pathology results and help guide care and long-term outcomes for adults having cancer surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 850 (estimated) |
| Sponsor | XEOS Medical Industry-sponsored |
| Locations | 5 sites (Aalst and 4 other locations) |
| Status | Recruiting |
| Started | November 19, 2025 |
| Main results expected | January 15, 2031 |
| Study ends | January 15, 2031 |
| Registry record updated | September 15, 2026 |
| Trial ID | NCT06970275 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults scheduled for resective cancer surgery whose resected specimens are successfully imaged with the XEOS AURA 10 and who consent to use of their medical records are ideal candidates.
✕Probably not a fit
Patients under 18, pregnant or breastfeeding women, and cases where the specimen image is technically uninterpretable are not expected to benefit from inclusion in this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry collects high-resolution PET-CT images made with the XEOS AURA 10 from resected tumor specimens and links those images to intraoperative impressions, histopathology, and follow-up outcomes. Both prospectively imaged patients and retrospectively included cases with prior successful specimen imaging may be entered if consent or notification requirements are met. Technical quality checks ensure included images contain at least part of the primary tumor and are interpretable. Analyses will describe concordance between specimen imaging and pathology and explore whether the imaging influenced clinical decisions or predicted long-term outcomes.
Why it matters
Potential benefit: If successful, this approach could improve detection of residual tumor or margin status on surgical specimens and better inform postoperative care and surveillance.
How similar studies have gone: Specimen-level PET imaging is a relatively novel approach with some pilot data suggesting promising correlation with pathology, but large-scale prospective evidence is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria : All patients that were scheduled for resective surgery and for whom successful high-resolution PET-CT imaging was performed on their resected specimens using the AURA 10 PET-CT. Successful imaging means that the image contains at least a portion of the primary tumor, the radiotracer injection was correctly executed and there were no technical issues that lead to an uninterpretable PET-CT image. Or all patients that are scheduled for resective surgery and for whom high-resolution PET-CT imaging will be performed on their resected specimens using the AURA 10 PET-CT. Patients willing to provide informed consent for use of their relevant medical records. For retrospectively included patients with no further Long-Term Follow-Up (LTFU) data collection, a notification will be sent. Exclusion Criteria: * Under the age of 18 years at the time of resective surgery. * Women who are pregnant or breastfeeding.
Where it's running
-
AZ Maria Middelares
Ghent, Belgium Recruiting -
Universitäts-klinikum Essen
Essen, North Rhine-Westphalia, Germany Recruiting -
Umcg
Groningen, Netherlands Recruiting -
University Hospitals Coventry and Warwickshire (UHCW) NHS Trust
Coventry, West Midlands, United Kingdom Recruiting -
Azorg
Aalst, Belgium Not yet recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers
This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.
-
Blood extracellular vesicles to detect chemotherapy-related nerve damage.
We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.
-
CAIX-targeted 18F-T2 PET/CT imaging in solid tumors
This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.
-
High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)
This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.
-
Riluzole to prevent thinking and memory problems during chemotherapy
This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.
-
OCT-598 for advanced solid tumors
This trial tests whether OCT-598, by itself or with docetaxel, is safe and to find the best dose for adults with advanced solid tumors who have limited standard treatment options.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.